Specific gene signatures in blood samples can help predict which neuroendocrine tumor patients will respond best to peptide receptor radionuclide therapy (PRRT).
59 + 66 patientsDiscovery and evaluation cohorts profiled via blood RNA-Seq to identify PRRT response markers
What the researchers found
Systemic cancer hallmark gene signatures in peripheral blood were significantly associated with progression-free survival in PRRT-treated GEP-NET patients, with cell cycle and immune-related pathways showing the strongest predictive value.
Why it matters
PRRT is a key peptide-based treatment for advanced neuroendocrine tumors, but predicting who will benefit most remains difficult. Blood-based biomarkers could enable personalized treatment decisions without invasive biopsies.
The numbers in context
- Discovery cohort: 59 GEP-NET patients + 38 healthy controls
- Evaluation cohort: 66 GEP-NET patients
- 30 cancer hallmarks differentially enriched in patients vs controls
- 2 hallmarks (heme metabolism, IL2/STAT5) independently predicted PFS in both cohorts (p<0.05)
How the study worked
Prospective cohort study using RNA-Seq on peripheral blood from a discovery cohort (59 PRRT-naïve GEP-NET patients + 38 healthy controls) and an independent evaluation cohort (66 GEP-NET patients). Cancer hallmark gene set enrichment was correlated with progression-free survival.
Who was studied
Discovery: 59 PRRT-naive GEP-NET patients + 38 healthy controls. Evaluation: 66 GEP-NET patients. Peripheral blood RNA-Seq profiling.
What this study cannot tell us
Relatively small cohort sizes; single-center study design; RNA-Seq from peripheral blood may not fully reflect tumor biology; requires prospective validation before clinical implementation.
How to read the evidence
Prospective cohort study with independent validation cohort, providing moderate-strength evidence. Limited by small sample sizes and need for multi-center replication.
When this study was published
Published in 2025, reflecting current state-of-the-art in PRRT biomarker research.
The bigger picture
This study represents a step toward precision medicine in peptide receptor radionuclide therapy. If validated in larger trials, blood transcriptomic profiling could become a routine tool for selecting optimal PRRT candidates and monitoring treatment response.
Questions still open
- Could these blood-based signatures also predict response to other peptide-based therapies beyond PRRT?
- How do these transcriptomic markers compare to established imaging-based predictors like SSTR expression?
- Would serial blood sampling during PRRT reveal dynamic changes in these cancer hallmark signatures?
Common questions
What is peptide receptor radionuclide therapy (PRRT)?
Could a simple blood test really predict cancer treatment outcomes?
Read the original research
Systemic Cancer Hallmarks as Novel Markers Associated with Progression-Free Survival in Gastroenteropancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
Neuroendocrinology, 115(12), 910-923
Citation
Padwal, Mahesh Kumar; Parghane, Rahul Vithalrao; Chakraborty, Avik; Ujaoney, Aman Kumar; Anaganti, Narasimha; Basu, Sandip; Basu, Bhakti. (2025). Systemic Cancer Hallmarks as Novel Markers Associated with Progression-Free Survival in Gastroenteropancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.. Neuroendocrinology, 115(12), 910-923. https://doi.org/10.1159/000542918